Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from FirstWord Pharma

15:36 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "FirstWord Pharma" found in our extensive news archives from over 250 global news sources.

More Information about FirstWord Pharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about FirstWord Pharma for you to read. Along with our medical data and news we also list FirstWord Pharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of FirstWord Pharma Companies for you to search.

Showing News Articles 1–25 of 551 from FirstWord Pharma

Friday 15th February 2019

Early-stage trial shows promising results for Opdivo, bempegaldesleukin combination in first-line urothelial carcinoma https://www.firstwordpharma.com/node/1625554?tsid=28®ion_id=6 …

Early-stage trial shows promising results for Opdivo, bempegaldesleukin combination in first-line urothelial carcinoma https://www.firstwordpharma.com/node/1625554?tsid=28&region_id=6 …

New US proposal calls for Medicare to cover CAR-T cell therapies https://www.firstwordpharma.com/node/1625470?tsid=28®ion_id=6 …

New US proposal calls for Medicare to cover CAR-T cell therapies https://www.firstwordpharma.com/node/1625470?tsid=28&region_id=6 …

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology https://firstwordpharma.com/node/1625421?tsid=33 …

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology https://firstwordpharma.com/node/1625421?tsid=33 …

Increased discount prompts NICE to recommend Roche's Perjeta after surgery for early breast cancer https://www.firstwordpharma.com/node/1625402  $RHHBY

Increased discount prompts NICE to recommend Roche's Perjeta after surgery for early breast cancer https://www.firstwordpharma.com/node/1625402  $RHHBY

Bayer, Orion focus on tolerability of darolutamide as they look to challenge Erleada, Xtandi in prostate cancer https://www.firstwordpharma.com/node/1625399  $BAY #GU19

Bayer, Orion focus on tolerability of darolutamide as they look to challenge Erleada, Xtandi in prostate cancer https://www.firstwordpharma.com/node/1625399  $BAY #GU19

Thursday 14th February 2019

Lundbeck, Otsuka's therapy brexpiprazole misses main goal of late-stage studies in bipolar disorder - FirstWord Pharma http://bit.ly/2TOfd7X  $LUN #pharma

Lundbeck, Otsuka's therapy brexpiprazole misses main goal of late-stage studies in bipolar disorder - FirstWord Pharma http://bit.ly/2TOfd7X  $LUN #pharma

AstraZeneca absorbs MedImmune brand as part of research unit overhaul https://www.firstwordpharma.com/node/1625248  $AZN

AstraZeneca absorbs MedImmune brand as part of research unit overhaul https://www.firstwordpharma.com/node/1625248  $AZN

Merck & Co. moves Keytruda into three pivotal combination studies for prostate cancer https://www.firstwordpharma.com/node/1625238  $MRK #GU19

Merck & Co. moves Keytruda into three pivotal combination studies for prostate cancer https://www.firstwordpharma.com/node/1625238  $MRK #GU19

Boehringer Ingelheim, Eli Lilly's DPP-4 inhibitor Tradjenta hits main goal of cardiovascular outcome study https://www.firstwordpharma.com/node/1625221  $LLY

Boehringer Ingelheim, Eli Lilly's DPP-4 inhibitor Tradjenta hits main goal of cardiovascular outcome study https://www.firstwordpharma.com/node/1625221  $LLY

Motif Bio's shares plunge after FDA seeks more data on iclaprim in complete response letter https://www.firstwordpharma.com/node/1625129  $MTFB

Motif Bio's shares plunge after FDA seeks more data on iclaprim in complete response letter https://www.firstwordpharma.com/node/1625129  $MTFB

AstraZeneca's revenue tops estimates in Q4, boosted by oncology product sales https://www.firstwordpharma.com/node/1625111  $AZN

AstraZeneca's revenue tops estimates in Q4, boosted by oncology product sales https://www.firstwordpharma.com/node/1625111  $AZN

Wednesday 13th February 2019

DBV Technologies to re-file Viaskin Peanut allergy treatment in US later this year https://www.firstwordpharma.com/node/1625083?tsid=28®ion_id=6 …

DBV Technologies to re-file Viaskin Peanut allergy treatment in US later this year https://www.firstwordpharma.com/node/1625083?tsid=28&region_id=6 …

Novartis sells US rights to cancer drug Proleukin to Clinigen for up to $210 million https://www.firstwordpharma.com/node/1624954?tsid=33 …

Novartis sells US rights to cancer drug Proleukin to Clinigen for up to $210 million https://www.firstwordpharma.com/node/1624954?tsid=33 …

Alvogen launches first #generic version of Celgene's Revlimid in certain European markets https://www.firstwordpharma.com/node/1624953  $CELG $BMY

Alvogen launches first #generic version of Celgene's Revlimid in certain European markets https://www.firstwordpharma.com/node/1624953  $CELG $BMY

Teva's shares fall nearly 10 percent on guidance for lower revenue, earnings in 2019 https://www.firstwordpharma.com/node/1624969  $TEVA

Teva's shares fall nearly 10 percent on guidance for lower revenue, earnings in 2019 https://www.firstwordpharma.com/node/1624969  $TEVA

Tuesday 12th February 2019

FDA advisory panel backs approval of Johnson & Johnson's depression drug Spravato http://bit.ly/2DAhNrc  $JNJ #FDA #pharma

FDA advisory panel backs approval of Johnson & Johnson's depression drug Spravato http://bit.ly/2DAhNrc  $JNJ #FDA #pharma

Mylan launches generic Wixela in US at 70-percent discount to GlaxoSmithKline's Advair http://bit.ly/2SJiHvk  $MYL #pharma

Mylan launches generic Wixela in US at 70-percent discount to GlaxoSmithKline's Advair http://bit.ly/2SJiHvk  $MYL #pharma

Sun Pharma's third-quarter profit surges as US sales climb 10 percent https://www.firstwordpharma.com/node/1624811 

Sun Pharma's third-quarter profit surges as US sales climb 10 percent https://www.firstwordpharma.com/node/1624811 

Merck & Co.'s Keytruda in combination with Pfizer's Inlyta cuts risk of death by 47 percent in renal cancer study https://www.firstwordpharma.com/node/1624774  $MRK #GU19

Merck & Co.'s Keytruda in combination with Pfizer's Inlyta cuts risk of death by 47 percent in renal cancer study https://www.firstwordpharma.com/node/1624774  $MRK #GU19

Monday 11th February 2019

Gilead's investigational therapy selonsertib misses main goal of late-stage study in compensated cirrhosis due to NASH http://bit.ly/2Sx4xOM  $GILD #pharma

Gilead's investigational therapy selonsertib misses main goal of late-stage study in compensated cirrhosis due to NASH http://bit.ly/2Sx4xOM  $GILD #pharma

Merck & Co.'s filing for Keytruda in first-line head and neck cancer gains FDA priority review https://www.firstwordpharma.com/node/1624568  $MRK

Merck & Co.'s filing for Keytruda in first-line head and neck cancer gains FDA priority review https://www.firstwordpharma.com/node/1624568  $MRK

AbbVie inks deal with Teneobio to develop BCMA-targeting bispecific antibody for multiple myeloma https://www.firstwordpharma.com/node/1624570  $ABBV

AbbVie inks deal with Teneobio to develop BCMA-targeting bispecific antibody for multiple myeloma https://www.firstwordpharma.com/node/1624570  $ABBV

Sanofi, Regeneron cut list price of PCSK9 inhibitor Praluent by 60 percent in the US https://www.firstwordpharma.com/node/1624561  $SNY $REGN

Sanofi, Regeneron cut list price of PCSK9 inhibitor Praluent by 60 percent in the US https://www.firstwordpharma.com/node/1624561  $SNY $REGN

Friday 8th February 2019

uniQure's investigational gene therapy AMT-061 continues to show sustained therapeutic levels of Factor IX activity in mid-stage haemophilia B trial https://www.firstwordpharma.com/node/1624085?tsid=28®ion_id=6 …

uniQure's investigational gene therapy AMT-061 continues to show sustained therapeutic levels of Factor IX activity in mid-stage haemophilia B trial https://www.firstwordpharma.com/node/1624085?tsid=28&region_id=6 …

ABPI says UK's participation in EU-wide anti-counterfeit medicine scheme at risk from 'no deal' Brexit https://www.firstwordpharma.com/node/1624060 

ABPI says UK's participation in EU-wide anti-counterfeit medicine scheme at risk from 'no deal' Brexit https://www.firstwordpharma.com/node/1624060 


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks